Clinical Research Directory
Browse clinical research sites, groups, and studies.
Impact of Reactogenicity of the 2024-2025 COVID-19 Vaccines on Health Care Workers and First Responders in the United States
Sponsor: Novavax
Summary
To assess the impact of reactogenicity among health care workers and first responders receiving an updated 2024-25 Novavax COVID-19 vaccine as compared with those receiving an updated 2024-25 Pfizer-BioNTech mRNA COVID-19 vaccine
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
660
Start Date
2024-09-20
Completion Date
2025-08-31
Last Updated
2025-03-10
Healthy Volunteers
Yes
Interventions
protein subunit: Novavax COVID-19 vaccine
Participants will receive a single dose (0.5 ml) of study vaccine Novavax COVID-19 vaccine, 2024-2025 formula (JN.1 containing) in the deltoid muscle of the arm.
Pfizer mRNA COVID-19 vaccine
Participants will receive a single dose (0.3 ml) of study vaccine Pfizer mRNA COVID-19 vaccine, 2024-2025 formula (KP.2 containing) in the deltoid muscle of the arm.
Locations (1)
University of Utah School of Medicine
Salt Lake City, Utah, United States